Literature DB >> 31035207

HIV-related care for transgender people: A systematic review of studies from around the world.

Anna Martha Vaitses Fontanari1, Gabriel Ibarra Zanella2, Marina Feijó2, Siobhan Churchill3, Maria Inês Rodrigues Lobato4, Angelo Brandelli Costa2.   

Abstract

RATIONALE: Transgender people face unique challenges, such as structural, interpersonal, and individual vulnerabilities to chronic diseases. Stigma and prejudice may hamper their access to health care and prevent their inclusion in the labor market, as well as cause exposition to violence. Labor market exclusion contributes to engagement in survival sex work, which increases HIV infection vulnerability. HIV continuum of care combines HIV prevention (including antiretroviral pre-exposure prophylaxis (PrEP), antiretroviral post-exposure prophylaxis (PEP) and HIV testing) with linkage to care (that is, initiating, maintaining and monitoring antiretroviral therapy). Currently, many studies evaluate the access barriers and facilitators to HIV care for transgender people.
OBJECTIVE: The present systematic review aimed to provide a clear summary of the current literature on HIV-related care for transgender men, transgender women and gender diverse people.
METHOD: Inclusion criteria were peer-reviewed quantitative studies, published through April 04, 2018, concerning transgender women, transgender men and gender diverse people and HIV-related care, which was any intervention aiming to prevent, treat or alleviate the impact of HIV on these populations.
RESULTS: From 6,585 references, 62 articles were included: Three articles had results on PEP, 18 on PrEP, 29 on HIV-testing, 17 on access to health care, and 13 on adherence to treatment.
CONCLUSIONS: The present study is the first systematic review evaluating HIV-related care for transgender people. Data collection is still scarce regarding transgender men and gender diverse people. Worldwide, testing for HIV infection does not necessarily enable access to the HIV continuum of care for transgender populations or even guarantee awareness of HIV seropositivity.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Access to health services; Adherence to treatment; Gender diverse people; HIV testing; PEP; PrEP; Transgender men; Transgender women

Mesh:

Substances:

Year:  2019        PMID: 31035207     DOI: 10.1016/j.socscimed.2019.03.016

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  16 in total

1.  Perceived acceptability and feasibility of HIV self-testing and app-based data collection for HIV prevention research with transgender women in the United States.

Authors:  Motolani Akinola; Andrea L Wirtz; Aeysha Chaudhry; Erin Cooney; Sari L Reisner
Journal:  AIDS Care       Date:  2021-01-23

2.  Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.

Authors:  Laura M Smeaton; Emma M Kileel; Beatriz Grinsztejn; Edward M Gardner; Kate Starr; Melissa L Murry; Patrice Desvigne-Nickens; Beverly Alston-Smith; Myron A Waclawiw; Katharine Cooper-Arnold; José V Madruga; Shashi Sangle; Kathleen V Fitch; Markella V Zanni; Pamela S Douglas; Heather J Ribaudo; Steven K Grinspoon; Karin L Klingman
Journal:  J Infect Dis       Date:  2020-07-09       Impact factor: 5.226

3.  Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review.

Authors:  Benedikt Pleuhs; Katherine G Quinn; Jennifer L Walsh; Andrew E Petroll; Steven A John
Journal:  AIDS Patient Care STDS       Date:  2020-02-28       Impact factor: 5.078

4.  Brief Report: Transgender Women and Preexposure Prophylaxis Care: High Preexposure Prophylaxis Adherence in a Real-World Health Care Setting in New York City.

Authors:  Lila Starbuck; Sarit A Golub; Augustus Klein; Alexander B Harris; Amiyah Guerra; Christopher Rincon; Asa E Radix
Journal:  J Acquir Immune Defic Syndr       Date:  2022-05-01       Impact factor: 3.771

5.  Prevention-effective adherence trajectories among transgender women indicated for PrEP in the United States: a prospective cohort study.

Authors:  Erin E Cooney; Sari L Reisner; Haneefa T Saleem; Keri N Althoff; S Wilson Beckham; Asa Radix; Christopher M Cannon; Jason S Schneider; J Sonya Haw; Allan E Rodriguez; Andrew J Wawrzyniak; Tonia C Poteat; Kenneth H Mayer; Chris Beyrer; Andrea L Wirtz
Journal:  Ann Epidemiol       Date:  2022-04-06       Impact factor: 6.996

6.  Studying physical and mental health status among hijra, kothi and transgender community in Kolkata, India.

Authors:  Shamayeta Bhattacharya; Debarchana Ghosh
Journal:  Soc Sci Med       Date:  2020-10-06       Impact factor: 4.634

7.  TransPrEP: Results from the Pilot Study of a Social Network-Based Intervention to Support PrEP Adherence Among Transgender Women in Lima, Peru.

Authors:  Jesse Clark; Sari Reisner; Amaya Perez-Brumer; Leyla Huerta; Hugo Sanchez; Kathleen Moriarty; Maria Mamani Luque; Hideaki Okochi; Ximena Salazar; Matthew Mimiaga; Jorge Sanchez; Monica Gandhi; Kenneth H Mayer; Javier R Lama
Journal:  AIDS Behav       Date:  2021-01-01

8.  Gender affirmative HIV care framework: Decisions on feminizing hormone therapy (FHT) and antiretroviral therapy (ART) among transgender women.

Authors:  Arjee J Restar; E Karina Santamaria; Alexander Adia; Jennifer Nazareno; Randolph Chan; Mark Lurie; Theo Sandfort; Laufred Hernandez; Susan Cu-Uvin; Don Operario
Journal:  PLoS One       Date:  2019-10-21       Impact factor: 3.240

Review 9.  Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review.

Authors:  Kenneth H Mayer; Allison Agwu; David Malebranche
Journal:  Adv Ther       Date:  2020-03-30       Impact factor: 3.845

10.  Condom-Protected Sex and Minority Stress: Associations with Condom Negotiation Self-Efficacy, "Passing" Concerns, and Experiences with Misgendering among Transgender Men and Women in Brazil.

Authors:  Ramiro Figueiredo Catelan; Alexandre Saadeh; Maria Inês Rodrigues Lobato; Daniel Augusto Mori Gagliotti; Angelo Brandelli Costa
Journal:  Int J Environ Res Public Health       Date:  2021-05-01       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.